Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSpectral Med Inc

Spectral Med Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.99 CAD 0.04 ( 4.21%)
Last update at 2026-11-04T19:32:00Z
VOLUME
1
Market Cap
399.05M

Momentum Score

…

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.95
Low
0.99
High
52 Week Price Range
0.77
Low
1.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Spectral Med Inc (EDT.TO) has limited public disclosures but is listed as a small-cap company operating in the medical/diagnostics sector developing clinical technologies. Long-term growth drivers may include product commercialization, strategic partnerships and expanded clinical adoption, which could support revenue scalability and make the company attractive to investors seeking exposure to medical-device development and potential milestone-driven upside.
Key risks include scarce public information, early-stage commercial and clinical execution risk, regulatory approval requirements, potential need for additional financing and low market liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.95
Dividend Yield
-
Revenue TTM
2.44M
Revenue Per Share
0.01
Gross Profit TTM
1.33M
Debt / Equity
-0.30
ROE
-973.97%
Net Debt
17.02M
ROCE
19.42%
Diluted EPS TTM
-0.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -47.69M -15.39M -15.51M -9.59M -8.79M
Net income -47.69M -15.40M -15.66M -11.30M -8.94M
Selling general administrative 11.73M 11.62M 4.83M 8.01M 9.43M
Selling and marketing expenses - - 6.47M - -
Gross profit -5.16M 1.02M 0.66M 0.98M 1.22M
Reconciled depreciation 0.25M 0.25M 0.22M 0.27M 0.29M
Ebit -11.69M -12.22M -14.17M -9.44M -8.60M
Ebitda -11.44M -11.97M -13.96M -9.17M -8.31M
Depreciation and amortization 0.25M 0.25M 0.22M 0.27M 0.29M
Operating income -11.69M -12.00M -11.42M -9.44M -8.60M
Other operating expenses 14.13M 14.28M 13.02M 8.92M 10.56M
Interest expense 5.16M 3.18M 1.33M 0.10M 0.03M
Net interest income 0.23M -3.18M -1.33M -0.10M -0.03M
Extraordinary items - -0.01M -0.15M -3.65M -
Income tax expense - - 0.15M 1.71M 0.16M
Total revenue 2.44M 2.29M 1.60M 1.67M 2.05M
Total operating expenses 6.53M 13.02M 12.08M 8.23M 9.73M
Cost of revenue 7.60M 1.27M 0.94M 0.68M 0.83M
Total other income expense net -36.00M -3.40M -4.09M -0.15M -0.18M
Discontinued operations - - - -3.65M -3.65M
Net income from continuing ops -47.69M -15.39M -15.51M -9.59M -8.79M
Net income applicable to common shares - -15.40M -15.66M -11.25M -8.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.10M 5.32M 5.21M 12.00M 11.55M
Intangible assets 0.33M 0.17M 0.19M 0.21M 0.23M
Other current assets 0.64M - 0.62M 0.28M 0.97M
Total liab 75.82M 32.87M 21.76M 14.52M 7.47M
Total stockholder equity -69.72M -27.55M -16.55M -2.52M 4.08M
Other current liab 47.67M 9.74M 7.53M 1.52M 1.08M
Common stock 95.93M - 87.06M 87.05M 84.36M
Capital stock 95.93M 90.57M 87.06M 87.05M 84.36M
Retained earnings -188.53M -140.84M -125.44M -109.74M -98.49M
Other liab - - - 4.01M 4.68M
Cash 4.07M 2.99M 2.95M 8.41M 8.89M
Total current liabilities 66.27M 27.45M 10.24M 3.96M 2.30M
Current deferred revenue 0.69M - 0.73M 0.70M 0.69M
Net debt 17.02M 11.44M 5.61M -1.77M -8.31M
Short term debt 16.57M - 0.39M 0.10M 0.09M
Short long term debt 16.43M 14.43M 0.26M - -
Short long term debt total 21.09M - 8.56M 6.64M 0.58M
Other stockholder equity 10.22M - 8.92M 20.17M 18.22M
Property plant equipment - - - 0.70M 1.06M
Total current assets 5.29M 4.46M 4.12M 10.09M 10.26M
Long term investments - 0.00M 0.00M 1.00M -
Net tangible assets - - - -2.73M 3.85M
Short term investments - - 0.61M - -
Net receivables 0.20M 0.30M 0.19M 1.06M 0.20M
Long term debt 4.75M - 7.68M 6.13M -
Inventory 0.38M 0.23M 0.37M 0.34M 0.29M
Accounts payable 1.34M 0.99M 1.60M 1.65M 0.44M
Accumulated other comprehensive income 12.66M - 12.91M - -
Non current assets total 0.81M 0.86M 1.09M 1.91M 1.29M
Capital lease obligations 0.37M 0.50M 0.62M 0.52M 0.58M
Long term debt total - - - 6.55M 0.49M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M -0.18M -0.03M -0.33M
Change to liabilities - - - 0.96M -1.27M
Total cashflows from investing activities -0.20M -0.03M -0.18M -0.03M -0.33M
Net borrowings 9.51M 9.74M 3.93M 6.71M -0.11M
Total cash from financing activities 12.91M 8.88M 5.44M 9.48M 12.16M
Change to operating activities - - - 0.60M -0.49M
Net income -47.69M -15.39M -15.66M -11.25M -8.79M
Change in cash 1.08M 0.04M -5.46M -0.48M 3.08M
Begin period cash flow 2.99M 2.95M 8.41M 8.89M 5.81M
End period cash flow 4.07M 2.99M 2.95M 8.41M 8.89M
Total cash from operating activities -11.63M -8.82M -10.72M -9.93M -8.70M
Issuance of capital stock - - 0.00M 4.03M 10.00M
Depreciation 0.25M 0.25M 0.22M 0.27M 0.29M
Other cashflows from investing activities - - - 0.00M 0.16M
Dividends paid 0.00M 0.00M 0.00M - -
Change to inventory -0.15M 0.14M -0.03M -0.05M -0.05M
Change to account receivables 0.25M -0.27M 0.87M -0.85M 0.06M
Sale purchase of stock - 1.15M - 4.11M 13.41M
Other cashflows from financing activities -0.15M -2.02M 1.51M 5.55M 2.28M
Change to netincome - - - 0.39M 1.55M
Capital expenditures 0.20M 0.03M 0.18M 0.03M 0.48M
Change in working capital -0.19M 1.01M -0.41M 0.66M -1.76M
Stock based compensation 2.12M 1.68M 1.49M 1.20M 1.26M
Other non cash items -11.69M 3.64M 3.64M -0.81M 0.29M
Free cash flow -9.72M -8.85M -10.91M -9.96M -9.18M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EDT
Spectral Med Inc		 0.04
4.21%		 0.99 - 99.01 163.41 52.98 171.77 -7.51

Profile*

Spectral Med Inc

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

135 The West Mall, Toronto, ON, Canada, M9C 1C2

416 626 3233

https://spectraldx.com

29

Name Title Year Born
Mr. Christopher Seto CEO & Director NA
Dr. John A. Kellum M.D. Chief Medical Officer NA
Ms. Debra-Anne M. Foster B.Sc., RN, CCRC VP of Clinical Devel. NA
Mr. Blair McInnis Chief Financial Officer NA
Mr. Sam Amory Pres of Dialco Medical Inc. NA
Mr. Christopher Seto CEO, CFO & Director NA
Mr. Christopher Seto CEO, Interim CFO & Director NA
Prof. John A. Kellum M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

LIF
CAD 21.93
+8.08%
CRON
CAD 5.29
+7.30%
CIA
CAD 2.05
+6.77%
THX
CAD 0.97
+5.43%
OGC
CAD 37.98
+5.38%
GIL
CAD 46.87
-22.45%
IFOS
CAD 1.70
-20.56%
ITH
CAD 1.99
-18.65%
KEEL
CAD 2.41
-17.75%
TNZ
CAD 51.05
-17.39%

Equity Sectors*

  • Basic Materials

    -2.08%

  • Communication Services

    +0.74%

  • Consumer Cyclical

    -2.22%

  • Consumer Defensive

    -0.50%

  • Energy

    -2.12%

  • Financial Services

    -1.76%

  • Healthcare

    -1.14%

  • Industrials

    -3.05%

  • Real Estate

    -0.47%

  • Technology

    -3.49%

  • Utilities

    -1.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…